The FDA on July 26, 2021 approved KEYTRUDA® for high-risk, early-stage, Triple-Negative Breast Cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA® is a product of Merck & Co.
Bottom Ad
Advertisement
Subscribe
